The Medical Letter - 2010
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Year:    Publication:      2010 Annual Index: U.S. English | Canadian English
January 11, 2010 (Issue 1329)  
January 25, 2010 (Issue 1330)  
  • Medical Marijuana   
    Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will...
  • Glucose Control in the ICU   
    Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill...
  • Ustekinumab (Stelara) for Psoriasis   
    The FDA has approved the use of ustekinumab (Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe...
February 8, 2010 (Issue 1331)  
February 22, 2010 (Issue 1332)  
March 8, 2010 (Issue 1333)  
March 22, 2010 (Issue 1334)  
April 5, 2010 (Issue 1335)  
  • Liraglutide (Victoza) for Type 2 Diabetes   
    Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2...
  • Plerixafor (Mozobil)   
    The FDA has approved plerixafor (Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen) to...
April 19, 2010 (Issue 1336)  
May 3, 2010 (Issue 1337)  
May 17, 2010 (Issue 1338)  
May 31, 2010 (Issue 1339)  
June 14, 2010 (Issue 1340)  
June 28, 2010 (Issue 1341)  
July 12, 2010 (Issue 1342)  
July 26, 2010 (Issue 1343)  
August 9, 2010 (Issue 1344)  
August 23, 2010 (Issue 1345)  
September 6, 2010 (Issue 1346)  
  • In Brief: Propoxyphene Toxicity   
    The FDA has required manufacturers of propoxyphene-containing products (Darvon, and others) to strengthen boxed warnings to include the potential for overdose.1 This action followed...
  • New Treatments for Metastatic Prostate Cancer   
    The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge – Dendreon) is the first immunotherapy approved...
  • Tribenzor for Hypertension   
    Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines...
  • Natazia - A New Oral Contraceptive   
    The FDA has approved the marketing of Natazia (Bayer), a 4-phase oral contraceptive containing the estrogen estradiol valerate and the progestin dienogest, both used for the first time in...
September 20, 2010 (Issue 1347)  
  • Dalfampridine (Ampyra) for MS   
    The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking...
  • Naproxen/Esomeprazole (Vimovo)   
    The FDA has approved the marketing of Vimovo (AstraZeneca), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) naproxen and the proton pump inhibitor (PPI)...
  • Nonstandard Uses of Chelation Therapy   
    Chelation therapy involves oral administration, intravenous infusion or intramuscular injection of drugs that increase excretion of heavy metals. The Medical Letter’s last article on this...
October 4, 2010 (Issue 1348)  
October 18, 2010 (Issue 1349)  
November 1, 2010 (Issue 1350)  
November 15, 2010 (Issue 1351)  
November 29, 2010 (Issue 1352)  
December 13, 2010 (Issue 1353)